Search research articles
Contact Us
Filters
Showing results (301-310 of 377) with videos related to
Page
of 38
Sort By:
Journal of Crohn'S & Colitis
|
June 6, 2023
Influence of Early Life Factors, including breast milk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease
João Sabino, Leonid Tarassishin, Caroline Eisele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 17, 2020
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium
Marc Fenster, Quazim A Alayo, Aava Khatiwada, et al.
The American Journal of Gastroenterology
|
June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
Jordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases
|
May 3, 2014
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease
Sylvie Rajca, Virginie Grondin, Edouard Louis, et al.
Inflammatory Bowel Diseases
|
April 29, 2025
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies
Stefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Gastroenterology
|
June 23, 2026
Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial
Gregory Rosenfeld, Neeraj Narula, Yvette Leung, et al.
United European Gastroenterology Journal
|
October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Tommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
The Journal of Experimental Medicine
|
December 12, 2024
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Joan Shang, Diane Marie Del Valle, Graham J Britton, et al.
Gut
|
August 9, 2024
Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families
Jonathan P Jacobs, Elizabeth A Spencer, Drew S Helmus, et al.
Page
of 38
Search research articles
Search
Showing results (301-310 of 377) with videos related to
Sort By:
Page
of 38
Journal of Crohn'S & Colitis
|
June 6, 2023
Influence of Early Life Factors, including breast milk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease
João Sabino, Leonid Tarassishin, Caroline Eisele, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 17, 2020
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium
Marc Fenster, Quazim A Alayo, Aava Khatiwada, et al.
The American Journal of Gastroenterology
|
June 15, 2016
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S Dulai, Siddharth Singh, Xiaoqian Jiang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 7, 2015
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents
Jordan Axelrad, Oren Bernheim, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases
|
May 3, 2014
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease
Sylvie Rajca, Virginie Grondin, Edouard Louis, et al.
Inflammatory Bowel Diseases
|
April 29, 2025
Comparing Outcomes With Subcutaneous Infliximab (CT-P13 SC) by Baseline Immunosuppressant Use: A Post Hoc Analysis of the LIBERTY-CD and LIBERTY-UC Studies
Stefan Schreiber, Jean-Frederic Colombel, Stephen B Hanauer, et al.
Gastroenterology
|
June 23, 2026
Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial
Gregory Rosenfeld, Neeraj Narula, Yvette Leung, et al.
United European Gastroenterology Journal
|
October 5, 2024
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective
Tommaso Lorenzo Parigi, Virginia Solitano, Alessandro Armuzzi, et al.
The Journal of Experimental Medicine
|
December 12, 2024
Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
Joan Shang, Diane Marie Del Valle, Graham J Britton, et al.
Gut
|
August 9, 2024
Age-related patterns of microbial dysbiosis in multiplex inflammatory bowel disease families
Jonathan P Jacobs, Elizabeth A Spencer, Drew S Helmus, et al.
Page
of 38